- JPM 2022: Bristol Myers plots 3 blockbuster launches to counter Revlimid's patent cliff
- Fierce Healthcare's Fierce 15 of 2022
- JPM22, Day 1: Bayer strikes a Mammoth deal, no Sunday buyouts, Pfizer delves deeper in gene editing and more
- Medtronic makes $925M offer for Affera, aiming to break into advanced cardiac mapping market
- Amid underwhelming Aduhelm launch, Biogen supports limited Medicare coverage, exec says
- Sarepta projects Duchenne muscular gene therapy will go to FDA next year, sees shares crash 15%
- Aduhelm price drop prompts Becerra to rethink hike to Part B 2022 premiums
- Acadia to Stoke up pipeline with $60M central nervous system research pact
- Merck, eyes on Roche’s immunotherapy first, returns perplexing Keytruda post-surgery lung cancer data
- Amicus axes gene therapy program for type of Batten disease, advances another
- Johnson & Johnson links up with Microsoft to cloud-connect its digital surgery programs
- JPM22, Day 1: CHOP leans on analytics during COVID-19 recovery, Oak Street expands on DOJ inquiry and more
- Exact Sciences moves into hereditary cancer tests with $190M PreventionGenetics buyout
- Say what you see: Novavax taps its own branding for latest COVID vaccine
Featured Story | By Eric Sagonowsky When Bristol Myers Squibb unveiled its massive Celgene buyout ahead of 2019's J.P. Morgan Healthcare Conference, executives knew Celgene's blockbuster blood cancer drug Revlimid would face generics sometime in the years that followed. In 2022, the key patent cliff is here. read more |
| |
|---|
|
Top Stories By Paige Minemyer Meet the winners of Fierce Healthcare's Fierce 15 of 2022. read more By Ben Adams,Annalee Armstrong,Conor Hale,Kyle LaHucik Join us for a rolling look at the top life sciences news coming out of this year's virtual J.P. Morgan Healthcare Conference. read more By Andrea Park Medtronic is already a strategic investor in Affera, with a 3% ownership stake in the Boston-based devicemaker. read more By Angus Liu Biogen is waiting with bated breath for a key reimbursement decision on Aduhelm from Medicare this week. With pushback mounting against the controversial Alzheimer’s disease therapy, the biotech isn’t picky for any potential coverage. read more By Kyle LaHucik Sarepta Therapeutics will ask the FDA to approve its gene therapy for Duchenne muscular dystrophy next year if the data from a pivotal trial is consistent with existing evidence, the biotech said at JPM 2022 on Monday. The biotech, with three approved DMD meds, said its gene therapy helped kids improve their motor skills. read more By Robert King HHS Secretary Xavier Becerra is asking CMS it take another look at 2022 Part B premium hikes now that Biogen cut the price of its controversial Alzheimer's disease drug Aduhelm in half. read more By Annalee Armstrong Acadia is looking to Stoke Therapeutics to breathe some air into its pipeline, with a $60 million upfront research pact to develop drugs for rare genetic diseases of the central nervous system. The upfront fee is accompanied by up to $907 million in milestones and also royalties down the line for Stoke. read more By Angus Liu Merck & Co.’s Keytruda reigns over the immuno-oncology market for metastatic lung cancer. But in controlling earlier-stage disease, the anti-PD-1 therapy has posted some new results that contradict the usual expectations. read more By Annalee Armstrong Amicus is moving on from an early-phase Batten disease program after follow-up data showed that the therapy didn't stop the fatal nervous system disease from progressing long-term. read more By Conor Hale Johnson & Johnson has tapped Microsoft to help build a cloud-connected software ecosystem around its digital surgery efforts. read more By Heather Landi,Paige Minemyer,Dave Muoio,Robert King,Rebecca Torrence,Anastassia Gliadkovskaya Advocate Aurora gave an update on the non-profit hospital chain's efforts to pivot to a consumer-related healthcare company, including new acquisitions in technology providers. read more By Conor Hale Exact Sciences has snapped up testing laboratory PreventionGenetics to expand its diagnostics franchise into hereditary cancer screening. Announced as the J.P. Morgan healthcare conference, the deal is a "natural fit," CEO Kevin Conroy said. read more By Ben Adams COVID vaccines are like buses. You wait hours for one, and then suddenly four come along. We’ve had Pfizer-BioNTech’s Comirnaty, Moderna’s Spikevax and AstraZeneca’s Covishield. Now, with a green light in Europe, there's Novavax—and it’s gone with a say-what-you-see approach to naming. read more |
|
